Rain Therapeutics nets $18M to push lung cancer asset into phase 2

Rain Therapeutics raised $18.4 million in series A funding, which will advance its lead program, a hypoxia-activated prodrug, in a population of patients with non-small cell lung cancer for whom there are no treatments.